Junshi Biosciences(688180) 每日经济新闻·2025-03-27 15:02Core Insights - Junshi Biosciences (SH688180) reported a revenue of 1.948 billion yuan for 2024, representing a year-on-year growth of 29.67% [1] - The company recorded a net loss of 1.281 billion yuan, which is a 43.90% reduction compared to the previous year [1] - The increase in revenue is attributed to the growth in sales of commercialized drugs [1] Revenue and Profitability - The main commercialized products include Toripalimab injection (brand name: Tuoyi), Adalimumab injection (brand name: Junmaikang), Dexamethasone Hydrochloride tablets (brand name: Mindewi), and Ongericimab injection (brand name: Junshida) [1] - Toripalimab remains the revenue driver, achieving domestic sales of 1.501 billion yuan in 2024, a year-on-year increase of approximately 66% [1] - The growth in Toripalimab's sales is linked to the approval of four new indications in 2024, bringing the total to 11 indications [1] Research and Development - The R&D expenses for Junshi Biosciences in 2024 were 1.275 billion yuan, a decrease of 34.18% year-on-year [2] - The number of R&D personnel decreased from 736 to 620 [2] Strategic Focus - The company is implementing a "quality improvement and efficiency enhancement" action plan to strengthen cost control and improve sales efficiency [1] - Resources are being concentrated on more promising R&D projects to further reduce losses [1]